Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Influenza A Virus, H7N9 Subtype | 4 | 2018 | 415 | 0.85 | Why? |
| Influenza in Birds | 5 | 2017 | 528 | 0.50 | Why? |
| Infectious Disease Incubation Period | 1 | 2020 | 1033 | 0.47 | Why? |
| Influenza, Human | 10 | 2021 | 10779 | 0.43 | Why? |
| Hand, Foot and Mouth Disease | 1 | 2011 | 115 | 0.40 | Why? |
| Poultry | 4 | 2017 | 437 | 0.36 | Why? |
| Rubella | 2 | 2019 | 127 | 0.33 | Why? |
| China | 23 | 2021 | 50654 | 0.29 | Why? |
| Epidemics | 3 | 2020 | 6407 | 0.27 | Why? |
| Sex Factors | 2 | 2021 | 11014 | 0.27 | Why? |
| Thyroid Neoplasms | 2 | 2019 | 422 | 0.26 | Why? |
| Age Factors | 4 | 2021 | 21039 | 0.23 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.21 | Why? |
| Morbillivirus | 1 | 2019 | 27 | 0.20 | Why? |
| Japanese Encephalitis Vaccines | 1 | 2019 | 14 | 0.20 | Why? |
| Rubella virus | 1 | 2019 | 46 | 0.19 | Why? |
| Transcription Factor AP-1 | 1 | 2019 | 75 | 0.19 | Why? |
| Encephalitis Virus, Japanese | 1 | 2019 | 63 | 0.19 | Why? |
| Rubella Vaccine | 1 | 2018 | 17 | 0.19 | Why? |
| Encephalitis, Japanese | 1 | 2019 | 58 | 0.18 | Why? |
| Communicable Diseases, Emerging | 2 | 2019 | 2523 | 0.17 | Why? |
| Case Management | 1 | 2020 | 285 | 0.17 | Why? |
| Students, Medical | 1 | 2017 | 4032 | 0.17 | Why? |
| Disease Transmission, Infectious | 2 | 2020 | 9044 | 0.17 | Why? |
| Lymphatic Metastasis | 1 | 2019 | 537 | 0.16 | Why? |
| Rain | 1 | 2017 | 108 | 0.16 | Why? |
| Rabies Vaccines | 1 | 2017 | 106 | 0.16 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.16 | Why? |
| Measles-Mumps-Rubella Vaccine | 1 | 2019 | 282 | 0.15 | Why? |
| Rabies | 1 | 2017 | 113 | 0.15 | Why? |
| Hepatitis B Vaccines | 1 | 2017 | 245 | 0.14 | Why? |
| Young Adult | 12 | 2021 | 93724 | 0.14 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.13 | Why? |
| Disease Notification | 1 | 2019 | 639 | 0.13 | Why? |
| Immunization Schedule | 2 | 2019 | 1305 | 0.13 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.12 | Why? |
| Lymph Nodes | 1 | 2019 | 1060 | 0.12 | Why? |
| Cluster Analysis | 2 | 2018 | 3001 | 0.12 | Why? |
| Adolescent | 10 | 2021 | 86841 | 0.12 | Why? |
| Early Diagnosis | 1 | 2021 | 2443 | 0.12 | Why? |
| Poultry Diseases | 1 | 2017 | 588 | 0.11 | Why? |
| Disease Eradication | 1 | 2018 | 581 | 0.11 | Why? |
| Measles | 1 | 2019 | 608 | 0.11 | Why? |
| Child, Preschool | 5 | 2021 | 36283 | 0.11 | Why? |
| Vaccination Coverage | 2 | 2018 | 1249 | 0.11 | Why? |
| Hepatitis B, Chronic | 1 | 2017 | 616 | 0.10 | Why? |
| Population Surveillance | 4 | 2019 | 4967 | 0.10 | Why? |
| Hepatitis B virus | 1 | 2017 | 882 | 0.10 | Why? |
| Child | 8 | 2021 | 70012 | 0.09 | Why? |
| Disease Outbreaks | 3 | 2020 | 27595 | 0.09 | Why? |
| Infant | 5 | 2021 | 30274 | 0.09 | Why? |
| Vaccination | 3 | 2019 | 19050 | 0.09 | Why? |
| Birds | 1 | 2011 | 412 | 0.09 | Why? |
| Beijing | 2 | 2021 | 912 | 0.08 | Why? |
| Infant, Newborn | 3 | 2021 | 23105 | 0.08 | Why? |
| Malaria | 1 | 2017 | 1097 | 0.08 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.08 | Why? |
| Adult | 14 | 2021 | 244371 | 0.08 | Why? |
| Public Health | 2 | 2021 | 16359 | 0.08 | Why? |
| Influenza Vaccines | 2 | 2017 | 2941 | 0.08 | Why? |
| Incidence | 4 | 2021 | 25622 | 0.08 | Why? |
| Humans | 28 | 2021 | 930598 | 0.07 | Why? |
| Male | 16 | 2021 | 367725 | 0.07 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.07 | Why? |
| Female | 16 | 2021 | 380317 | 0.07 | Why? |
| Aged | 9 | 2021 | 215776 | 0.07 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.07 | Why? |
| Health Services Needs and Demand | 1 | 2019 | 3419 | 0.07 | Why? |
| Models, Statistical | 1 | 2021 | 5312 | 0.06 | Why? |
| Immunogenicity, Vaccine | 1 | 2019 | 4624 | 0.06 | Why? |
| Sentinel Surveillance | 1 | 2011 | 1093 | 0.06 | Why? |
| Respiratory Tract Infections | 2 | 2021 | 6817 | 0.06 | Why? |
| Influenza A Virus, H5N1 Subtype | 1 | 2006 | 492 | 0.06 | Why? |
| Public Health Administration | 1 | 2011 | 846 | 0.06 | Why? |
| Communicable Disease Control | 3 | 2020 | 29620 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.06 | Why? |
| Animals | 6 | 2017 | 78931 | 0.05 | Why? |
| Influenza A virus | 1 | 2013 | 2234 | 0.05 | Why? |
| History, 21st Century | 2 | 2018 | 1849 | 0.05 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.05 | Why? |
| Mandatory Testing | 1 | 2019 | 67 | 0.05 | Why? |
| Pneumonia | 1 | 2019 | 5652 | 0.05 | Why? |
| JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 59 | 0.05 | Why? |
| Neck Dissection | 1 | 2019 | 109 | 0.05 | Why? |
| Thyroid Nodule | 1 | 2019 | 70 | 0.05 | Why? |
| Mandatory Reporting | 1 | 2019 | 140 | 0.04 | Why? |
| Matrix Metalloproteinase 9 | 1 | 2019 | 211 | 0.04 | Why? |
| Tumor Burden | 1 | 2019 | 369 | 0.04 | Why? |
| Statistics, Nonparametric | 1 | 2021 | 1008 | 0.04 | Why? |
| Work Engagement | 1 | 2019 | 154 | 0.04 | Why? |
| Neck | 1 | 2019 | 307 | 0.04 | Why? |
| Calcinosis | 1 | 2019 | 240 | 0.04 | Why? |
| Technology, Pharmaceutical | 1 | 2017 | 82 | 0.04 | Why? |
| Seasons | 2 | 2021 | 4071 | 0.04 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.04 | Why? |
| Nonlinear Dynamics | 1 | 2017 | 177 | 0.04 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.04 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.04 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.04 | Why? |
| Immunization Programs | 2 | 2018 | 2006 | 0.03 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.03 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Vaccines, Attenuated | 1 | 2019 | 952 | 0.03 | Why? |
| Oseltamivir | 1 | 2017 | 583 | 0.03 | Why? |
| Orthomyxoviridae | 1 | 2021 | 1168 | 0.03 | Why? |
| Climate | 1 | 2017 | 557 | 0.03 | Why? |
| Immunohistochemistry | 1 | 2019 | 2275 | 0.03 | Why? |
| Program Evaluation | 1 | 2019 | 1929 | 0.03 | Why? |
| Reassortant Viruses | 1 | 2013 | 287 | 0.03 | Why? |
| History, 20th Century | 1 | 2017 | 1282 | 0.03 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.02 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.02 | Why? |
| Seroconversion | 1 | 2019 | 2515 | 0.02 | Why? |
| Hemagglutination, Viral | 1 | 2006 | 31 | 0.02 | Why? |
| Pilot Projects | 1 | 2019 | 5182 | 0.02 | Why? |
| SARS Virus | 1 | 2011 | 13021 | 0.02 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2011 | 12361 | 0.02 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.02 | Why? |
| ROC Curve | 1 | 2019 | 6024 | 0.02 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.02 | Why? |
| Aluminum Hydroxide | 1 | 2006 | 133 | 0.02 | Why? |
| Hemagglutination Inhibition Tests | 1 | 2006 | 191 | 0.02 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2019 | 7220 | 0.02 | Why? |
| Cities | 1 | 2017 | 4937 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2013 | 2830 | 0.02 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.02 | Why? |
| Quarantine | 2 | 2021 | 18418 | 0.02 | Why? |
| Fatal Outcome | 1 | 2013 | 3438 | 0.02 | Why? |
| Zoonoses | 1 | 2017 | 3034 | 0.02 | Why? |
| Travel | 1 | 2021 | 7220 | 0.01 | Why? |
| Fever | 1 | 2019 | 7795 | 0.01 | Why? |
| Practice Patterns, Physicians' | 1 | 2019 | 4927 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2019 | 17020 | 0.01 | Why? |
| Vero Cells | 1 | 2017 | 14117 | 0.01 | Why? |
| Vaccines, Inactivated | 1 | 2006 | 1562 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2019 | 22971 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 2006 | 3776 | 0.01 | Why? |
| Adjuvants, Immunologic | 1 | 2006 | 1709 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Double-Blind Method | 1 | 2006 | 5988 | 0.01 | Why? |
| Antibodies, Viral | 2 | 2019 | 51949 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2019 | 21571 | 0.01 | Why? |
| Phylogeny | 1 | 2013 | 13341 | 0.01 | Why? |
| United States | 1 | 2021 | 46150 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 11367 | 0.01 | Why? |
| Treatment Outcome | 1 | 2019 | 51732 | 0.01 | Why? |
| Genome, Viral | 1 | 2013 | 13157 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2017 | 25288 | 0.01 | Why? |
| Hospitalization | 1 | 2019 | 54280 | 0.01 | Why? |
| Antiviral Agents | 1 | 2017 | 41703 | 0.00 | Why? |
Feng's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(155)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(217)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_